India Globalization (IGC) Reports Prelim Results from Phase 1 Trial of IGC-AD1 for Alzheimer’s Patients

December 8, 2021 5:44 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

India Globalization Capital, Inc. (NYSE American: IGC) today announces preliminary results for its exploratory endpoints from its Phase 1 IGC-AD1 clinical trial. IGC-AD1 is a proprietary cannabis-based investigational new drug candidate for patients suffering from Alzheimer’s disease. The Phase 1 clinical trial provided valuable insights on Pharmacokinetics (PK) and genotyping that will be essential in determining optimal dosing moving into subsequent trials, subject to U.S. Food and Drug Administration (FDA) approval.

The clinical trial results were submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA on December 1, 2021. In addition, as previously disclosed, data from the secondary endpoints, neuropsychiatric symptoms in Alzheimer’s patients, and other relevant data are available on Form 8-K filed with the SEC on December 2, 2021.

Alzheimer’s disease impacts about 50 million people worldwide, and approximately 66% are women (alz.org). Unfortunately, there is no cure for Alzheimer’s and no FDA-approved pharmaceuticals to treat many of the symptoms, including agitation, in Alzheimer’s.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

FDA